A Phase II, Open Study of the Clinical Activity, Safety and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB-2-Overexpressing Breast Cancer

Sponsor: GlaxoSmithKline

Location(s): United States


This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.